Genentech, Inc.

Genetech, Inc.

F. Hoffmann-la Roche Ag

Gerald R Nakamura

Nancy Chiang

Mercedesz Balazs

Henry Chiu

Zhonghua Lin

Ning Chai

Hyunjoo Park

Min Xu

Henry Bernard Lowman

Menno Van Lookeren Campagne

Phillip W Berman

Lee R Swem

Dhaya Seshasayee

Jack Bevers, Iii

Hongkang Xi

Philip E Hass

Wenwu Zhai

Leonard G Presta

Camellia W Adams

Patrick J Lupardus

Meredith C Hazen

Yi-Chun Hsiao

Rajita Khosla

Andrew C Chan

Craig W Crowley

Mark E Reynolds

Melissa A Starovasnik

Leonard Presta

Laetitia Comps-Agrar

Saloumeh Kadkhodayan Fischer

Lee Swern

Racquel Corpuz

Hiu Nam Chan

Jia Wu

Tiffany Wong

Dana L Baker

Zhaoyu Jin

Saloumeh Fischer

Jack Iii Bevers

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same.

Anti-influenza B virus hemagglutinin antibodies and methods of use

The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.

Assays for detecting antibodies specific to therapeutic anti-IgE antibodies and their use in anaphylaxis

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Immunoglobulin variants and uses thereof

The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated Fc&#x3b5;RI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides composition, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.

IgE receptor antagonists

A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used.to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine. A DNA sequence encoding gp120 from preferred vaccine strains of HIV, GNE and GNE , expression constructs comprising the GNE -gp120 and GNE -gp120 encoding DNA under the transcriptional and translational control of a heterologous promoter, and isolated GNE -gp120 and GNE -gp120 are also described.

HIV envelopolype peptides

A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4-domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine. A DNA sequence encoding gp120 from preferred vaccine strains of HIV, GNE,and GNE,, expression constructs comprising the GNE,-gp120 and GNE,-gp120 encoding DNA under the transcriptional and translational control of a heterologous promoter, and isolated GNE,-gp120 and GNE,-gp120 are also described.

HIV envelope polypeptides

Growing community of inventors

San Francisco, CA, United States of America

Gerald R Nakamura